3.48
-0.63(-15.33%)
Currency In USD
| Previous Close | 4.11 |
| Open | 4.23 |
| Day High | 4.23 |
| Day Low | 3.26 |
| 52-Week High | 4,905 |
| 52-Week Low | 3.32 |
| Volume | 181,632 |
| Average Volume | 203,552 |
| Market Cap | 2.63M |
| PE | -0.01 |
| EPS | -255.6 |
| Moving Average 50 Days | 9.8 |
| Moving Average 200 Days | 102.78 |
| Change | -0.63 |
If you invested $1000 in Conduit Pharmaceuticals Inc. (CDT) since IPO date, it would be worth $0.23 as of May 24, 2025 at a share price of $3.48. Whereas If you bought $1000 worth of Conduit Pharmaceuticals Inc. (CDT) shares 2 years ago, it would be worth $0.22 as of May 24, 2025 at a share price of $3.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
GlobeNewswire Inc.
May 22, 2025 12:30 PM GMT
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for comp
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
GlobeNewswire Inc.
May 21, 2025 12:30 PM GMT
Conduit regains compliance with Bid Price and Equity RequirementsCDT will continue to be listed and traded on The Nasdaq Stock Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq:
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
GlobeNewswire Inc.
May 09, 2025 12:30 PM GMT
Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnershi